Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
LPL contributes profoundly to physiologic lipoprotein metabolism and to tissue-specific substrate delivery and utilization (1). Perturbed LPL activity affects global energy balance, insulin action, body weight maintenance, and CVD risk; the latter alluded to by contemporary human genetic studies. LPL is the pivotal rate-limiting mediator of hydrolysis of core TGs from TG-rich lipoproteins, particularly chylomicrons and VLDL (2, 3). The products of LPL-mediated catalysis, such as fatty acids and monoacylglycerol, are handled differentially at local sites depending on the global hormonal and nutritional milieu, and local energy needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Apo C-II is a cofactor for LPL91,92”
From Clinical review on triglycerides (2020) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“However, apo C-II has not been genetically validated as a target for ASCVD.91”
From Clinical review on triglycerides (2020) · cites this paper as [91]
In the citing paper
“Finally, angiopoietin-like protein 4 (ANGPTL4) regulates LPL activity, analogous to ANGPTL3, but its mechanism is incompletely defined.91,97,98”
From Clinical review on triglycerides (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 3×
“Loss of apoA-V function is positively correlated with elevated plasma TG and increased CHD risk (44, 45).”
BackgroundLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921 · cited 1×
“able apolipoprotein discovered bioinformatically (42),”
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754 · cited 1×
““familial combined hypolipidemia” or “familial hypobetalipoproteinemia type 2” (18, 49).”
BackgroundLipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741 · cited 1×
“LPL contributes profoundly to physiologic lipoprotein metabolism and to tissue-specific substrate delivery and utilization (1).”
BackgroundTriglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716 · cited 1×
“Another common functional APOA5 variant, namely the −1131C>T promoter variant, was associated with increased TG, reduced HDL cholesterol, and increased CHD risk in a meta-analysis of 101 studies (46).”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650 · cited 2×
“Loss of apoA-V function is positively correlated with elevated plasma TG and increased CHD risk (44, 45).”
BackgroundSelf-citationPhysiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550 · cited 6×
“In contrast, common small-effect LPL loss-of-function variants in the general population are associated with milder increases in plasma TGs, due in part to impaired clearance of VLDL (5).”
BackgroundInfluential
Cited by
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
“Alipogene tiparvovec (Glybera; uniQure, Lexington, MA, USA) gene therapy for LPL deficiency was available in Europe until 2017, when the sponsor declined to renew market authorization.”
BackgroundInfluentialSelf-citationGenetics of hypertriglyceridemia
Dron, J. S., & Hegele, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00455 · Cited by 244
Self-citationThe interplay of factors in metabolic syndrome: understanding its roots and complexity
Islam, M. S., Wei, P., Suzauddula, M., Nime, I., Feroz, F., Acharjee, M., & Pan, F. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01019-y · Cited by 169
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
“In patients with severe hypertriglyceridemia, atherosclerosis risk is increased among individuals who have a diffuse spectrum of large TG-rich chylomicron remnants (ie, polygenic chylomicronemia) but not among those with pure monogenic chylomicronemia.(74) Elevated TG levels are consistently associated with ASCVD in e…”
BackgroundInfluentialSelf-citationRegmi, A., Aihara, E., Christe, M. E., Varga, G., Beyer, T. P., Ruan, X., Beebe, E., O’Farrell, L. S., Bellinger, M. A., Austin, A. K., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.010 · Cited by 130
Genetics of Triglycerides and the Risk of Atherosclerosis
Dron, J. S., & Hegele, R. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0667-9 · Cited by 110
Self-citationLipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors
Morel, S., Leahy, J., Fournier, M., Lamarche, B., Garofalo, C., Grimard, G., Poulain, F., DELVIN, E. E., Laverdière, C., Krajinović, M., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m072207 · Cited by 69
Huth, C., von Toerne, C., Schederecker, F., de las Heras Gala, T., Herder, C., Kronenberg, F., Meisinger, C., Rathmann, W., Koenig, W., Waldenberger, M., et al. (2019) · European Journal of Epidemiology · doi:10.1007/s10654-018-0475-8 · Cited by 56
Lipid Transport in Brown Adipocyte Thermogenesis
Wade, G., McGahee, A., Ntambi, J. M., & Simcox, J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.787535 · Cited by 57
“ANGPTLs are secreted into the lumen and directly interact with LPL, preventing its dimerization and inhibiting lipolysis (Hegele, 2016).”
BackgroundSafety and efficacy of therapies for chylomicronemia
Shamsudeen, I., & Hegele, R. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2094768 · Cited by 37
“Finally, APOA5 endcoding apo A-V has been considered as another drug target that when upregulated theoretcialy could reduce TG levels [56].”
BackgroundSelf-citationGao, M., Yang, C., Wang, X., Guo, M., Liu, Y., Gao, S., Zhang, X., Ruan, G., Li, X., Tian, W., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154296 · Cited by 37
DIABETES MELLITUS: THE MODERN STATE OF THE ISSUE (PART 1)
Sharofova, M. U., Самаровна, С. Ш., & Yusufi, S. J. (2019) · Avicenna Bulletin · doi:10.25005/2074-0581-2019-21-3-502-512 · Cited by 25
“Инсулин также регулирует выраженность базальной липопротеин-липазы, активность ряда других белков [36-38].”
Zhao, Q., Zhou, X., Kuiper, R., Curbo, S., & Karlsson, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270418 · Cited by 18
“Lipoprotein lipase, encoded by the Lpl gene, is an enzyme that can both hydrolyze triglycerides and mediate lipoprotein uptake [16].”
BackgroundLee, P. C., Jung, I., Thussu, S., Patel, V., Wagoner, R., Burks, K. H., Amrute, J., Elenbaas, J. S., Kang, C. J., Young, E. P., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110104 · Cited by 12
“32,34,58 61 Additionally, we nominate COL6A3-derived peptide endotrophin and serine-protease HTRA1 as potential regulators of CAD risk.”
Jin, Y., Xie, Z., Li, S., Zeng, X., Wang, L., Hu, P., Zhang, H., & Xiao, X. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/5526778 · Cited by 12
“LPC (20 : 5), PCs, plasmalogens, PIs, PSs, SHexCer (t34 :1), SMs, CE (20 : 5), and TGs showed positive correlations with WBVs and FIB and negative correlations with PT, APTT, and TT.”
BackgroundInfluentialLipoprotein Lipase: A General Review
Andrade, M. C. (2018) · Insights in Enzyme Research · doi:10.21767/2573-4466.100013 · Cited by 11
“Regulation of LPL activity has so many different features that the adjective multidimensional would be perhaps more appropriate to qualify it [88].”
BackgroundGenetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 9
“Early genetic studies of families with CETP deficiency resulting from rare loss-of-function mutations in the CETP gene showed that patients had markedly elevated levels of highdensity lipoprotein (HDL) cholesterol together with apparent protection from CVD risk (36), while subsequent studies showed that carriers of th…”
InfluentialSelf-citationZhang, M., Yin, T., Xia, F., Xia, S., Zhou, W., Zhang, Y., Han, X., Zhao, K., Feng, L., Dong, R., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.960343 · Cited by 9
Jia, Q. Q., Yang, Z., Wang, Q., Zhao, Q. J., Jia, Y. J., Guo, B. H., Li, X., & Wang, W. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300683 · Cited by 7
Can Avicenna Help Manage the Diabetes Epidemic in Central Asia?
Sharofova, M. U., Nuraliev, Y., Sukhrobov, P., Самаровна, С. Ш., & Dushenkov, S. (2017) · Central Asian Journal of Medical Sciences · doi:10.24079/cajms.2017.11.002 · Cited by 5
Clinical heterogeneity in monogenic chylomicronaemia
Heidemann, B. E., Bemelmans, R. H. H., Marais, A. D., Visseren, F. L. J., & Koopal, C. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-251411 · Cited by 5
Davidson, J., & Rotondo, D. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000510 · Cited by 4
“LPL activity is increased by ApoA5 and inhibited by ApoC-III [9].”
BackgroundInfluentialMolecular Genetics of Hypertriglyceridaemia
Dron, J. S., & Hegele, R. A. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0026710 · Cited by 2
Self-citationCardiac Metabolomic Alterations in Diabetes: Interplay with Lipoprotein Lipase—A Systematic Review
Gu, J., Han, X., Chen, X., Lü, A., & Cheung, K. C.-P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311501 · Cited by 1
“This disruption in lipid homeostasis forms the core of the development of atherosclerosis and diabetic cardiomyopathy [8].”
InfluentialDysregulated Lipid Metabolism in Hepatocellular Carcinoma: Mechanisms and Therapeutic Strategies
Yi, Y., Liu, X., Zhang, X., Li, Y., & Zhao, H. (2026) · MedComm – Oncology · doi:10.1002/mog2.70081 · Cited by 1
Genetic lipid disorders, the APOE gene and Familial Dysbetalipoproteinemia
Heidemann, B. E. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1408
Taradeh, M. (2023) · theses.fr (ABES) · doi:10.70675/8cb53537z2270z4c15zb7b0za5a5fecc4fe3 · Cited by 2
Gong, Z., Xia, Y., Sun, C., Zheng, W., Du, T., Liang, L., Wang, R., Zhang, K., Yang, Y., Sun, M., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.07.010
Mueller, P. A., Rosário, S., Hay, J., Bergstrom, P., Pacheco-Velázquez, S. C., Hegele, R. A., Pamir, N., & Purnell, J. Q. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.04.196 · Cited by 1
Self-citationde Freitas, A. T. A. G. (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Ma, C., Zhao, W., Bao, Y., Yang, Q., Wu, L., Zhu, T., Sun, P., Zhou, Q., & Jin, M. (2026) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2026.101966
Metadata
- Authors
- Hegele, R. A.
- Affiliations
- Western University (CA)
- Corresponding author
- Hegele, Robert A.
- ORCID
- Hegele, Robert A.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 57
- Issue
- 9
- Pages
- 1601-1607
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC5003155
- OpenAlex
- W2475024711
- Cited by
- 31
- References
- 59
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 1 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 2
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 1462 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Heart and Stroke Foundation of Canada (G-15-0009214)
- Genome Canada
- Canadian Institutes of Health Research (G-15-0009214)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- lipoprotein lipase, lipoprotein metabolism, triglyceride-rich lipoproteins, chylomicrons, VLDL, cardiovascular risk, insulin action, energy balance, body weight, genetic variants, monoglycerides
- MeSH terms
- Apolipoproteins, Cardiovascular System, Cardiovascular Physiological Phenomena, Lipoprotein Lipase, Phenotype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.